ABUS Projected Dividend Yield
Arbutus Biopharma Corp ( NASDAQ : ABUS )Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer. 20 YEAR PERFORMANCE RESULTS |
ABUS Dividend History Detail ABUS Dividend News ABUS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |